1084 results about "Orally disintegrating tablet" patented technology

A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insoluble polymer and at least one gastrosoluble inorganic or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short T_max). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

A pharmaceutical dosage form such as a capsule, a conventional or orally disintegrating tablet capable of delivering a nitrogen (N)-containing therapeutic agent having a pKa in the range of from about 5 to 14 into the body in a sustained-released fashion, in order to be suitable for a twice- or once-daily dosing regimen, comprises at least one organic acid, which solubilizes the therapeutic agent the drug prior to releasing it into the hostile intestinal environment wherein said weakly basic drug is practically insoluble. The unit dosage form is composed of a multitude of multicoated particulates (i.e., immediate-release beads, sustained-release beads and/or one or more timed, pulsatile-release bead populations) is designed in such a way that said weakly basic drug and said organic acid do not come into close contact during processing and/or storage for in-situ formation of acid addition compounds while ensuring that the acid is not depleted prior to completion of the drug release.

The present invention relates to pharmaceutical compositions, and methods of preparing such compositions, comprising one or more populations of controlled-release particles comprising one or more proton pump inhibitors. The present invention also relates to pharmaceutical dosage forms, including orally disintegrating tablets, tablets, capsules, and methods for their preparation.

In various embodiments, the present invention is directed to a taste masked pharmaceutical composition comprising a therapeutically effective amount of taste masked sulfamate-substituted monosaccharide particles comprising a sulfamate-substituted monosaccharide or a pharmaceutically acceptable salt or derivative thereof that are coated with one or more taste-masking layers, and optionally one or more of taste-masked neltrexone, 5-HT₃ receptor antagonist, phentermine, and vitamin B-12. The present invention relates to methods of making the taste masked and ODT compositions, and methods of using the compositions for treating a patient subject to an epileptic condition, migraines, dysphagia, achieving/maintaining weight loss, or alcoholism or drug addiction.

The compositions of the present invention are orally disintegrating tablet compositions comprising a therapeutically effective amount of at least one drug such as temazepam, 0.5-3% of an ODT binder polymer, a sugar alcohol and/or saccharide, and a disintegrant.

The invention is directed to pharmaceutical dosage forms having immediate release via rapid oral disintegration, specifically, orally disintegrating tablets containing levodopa and carbidopa. The invention further provides formulations containing relatively increased amounts of carbidopa than previously available, including, for example, formulations containing carbidopa-levodopa ratios of about 1:1 to about 1:3.

The present invention relates to a memantine hydrochloride oral disintegrant tablet and its preparation method. Its composition includes (by wt%) 2-20% of memantine hydrochloride as active component, 20-92% of filling agent, 5-30% of disintegrant agent and 1-30% of corrective agent.

This invention relates to rapidly dispersing microgranules comprising at least one sugar alcohol or saccharide, at least one super disintegrant, and a pharmaceutically acceptable additive with multi-functionality (e.g., starch acting as a binder, disintegrant, diluent/filler, glidant, etc) at a low level, which can be formed by not only eliminating a wet milling step but also avoiding an extensive dry milling step. Furthermore, such rapidly dispersing microgranules could also comprise a pharmaceutically active agent thereby providing for a pharmaceutical composition, or the rapidly dispersing microgranules thus produced are suitable for blending with a pharmaceutically active agent that is optionally taste-masked and/or controlled release coated microparticles to also provide for a pharmaceutical composition and the invention is also directed to a method for manufacturing such rapidly dispersing microgranules in a high useable yield, as well as orally disintegrating tablets comprising such rapidly dispersing microgranules. The rapidly dispersing microgranules are also free flowing.

The present invention relates to taste-masked oral formulations of influenza antivirals. The taste-masked pharmaceutical formulations for oral administration comprise one or more influenza antivirals, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. Further, the taste-masked influenza antiviral formulations of the present invention are provided in the form of dispersible tablets, effervescent tablets, orally disintegrating tablets, chewable tablets, bite-dispersion tablets or the like, wherein the bitter taste of influenza antivirals is masked thereby providing palatable formulations.

There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, or a mixture thereof, and other optional, pharmaceutically acceptable excipients wherein the orally disintegrating tablet (ODT) or rapidly dispersing tablet (RDT) composition having acceptable tableting, organoleptic, and pharmacokinetic properties.

An orally-disintegrating tablet of fluterazole for treating tumor contains tegafur, Jimosite and potassium oxyazinate. It has agreeable taste.

The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a weakly basic drug core, a layer of alkaline buffer, and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation.

The invention discloses a water-insoluble medicine sustained-release pellet, a sustained-release orally disintegrating tablet thereof and a preparation method thereof. The water-insoluble medicine sustained-release pellet comprises a hollow pellet core, a medicine layer, an insulation layer and a sustained-release layer, wherein the sustained-release layer comprises the following ingredients: 54 to 88 percent of sustained-release materials, 2 to 30 percent of antitackiness agents and 1 to 30 percent of pore-foaming agents, wherein the percentage is the mass percentage in the sustained-release layer, wherein the sustained-release materials are one kind or several kinds of materials selected from ethyl acrylate and methyl methacrylate copolymers, polyvinyl acetate and ethyl cellulose. Through regulating the coating combinations and filling auxiliary materials to be pressed into orally disintegrating tablets, the medicine can be slowly released for more than 8 to 13 hours, so the stable blood medicine concentration can be maintained, the side effect is reduced, the medicine taking times can be reduced, and the medicine taking is convenient. The invention conforms to zero-grade release, has the advantages of high final accumulated medicine release amount, high efficacy, strong selectivity, good mouth feeling, simple production steps and high efficiency, and can be applied to large-scale production.

The invention relates to a synbiotics of bacillus licheniformis and oligosaccharide class prebiotics and a composite and a formulation thereof, being characterized in that the synbiotics comprises bacillus licheniformis medical live bacterial powder and the oligosaccharide class prebiotics, wherein the bacillus licheniformis medical live bacterial powder contains live bacteria about 30 billion/gram; the weight ratio of the bacillus licheniformis medical live bacterial powder to the oligosaccharide class prebiotics is 1:1 to 76; the weight ratio of the medical live bacterial powder of the composite, the oligosaccharide class prebiotics and auxiliary materials is as follows: 1.25-5 percent of the bacillus licheniformis medical live bacterial powder, 5-95 percent of the oligosaccharide class prebiotics, 20-50 percent of preferable oligosaccharide class prebiotics, 30-65 percent of diluting agents, 1-20 percent of bonding agents, 1-15 percent of disintegrating agents, 0.1-3 percent of lubricating agents, 1-10 percent of coating agents, 0.01-0.1 percent of flavoring agents, 0.0001-0.001 percent of coloring agents, and 0.1-15 percent of suspending agents. The synbiotics composite is prepared into oral common tablets, oral cavity disintegration tablets, dispersing tablets, enteric-coated tablets, granular formulation, enteric-coated granular formulation, capsules, enteric-coated capsules, dry supensoid agents and external tablets according to a conventional process; and an in vitro test shows that each formulation can promote the growth and the reproduction of the synbiotics of bacillus licheniformis, restrain the growth of harmful bacteria, enhance the immunizing power of parasitifers, reduce diarrhea and enhance the health care.

The tablets comprise: at least 59.5% spray-dried mannitol; active ingredient below or equal to 10%, where at least 90% in weight of the active ingredient has a particle size below 100 μm; microcrystalline cellulose 10-18%, with an average particle size of 50 μm and where at least 99% in weight of microcrystalline cellulose has a particle size below 250 μm; sodium croscarmellose 14%; and a lubricant agent 0.5-2%; where, unless specified otherwise, the percentages are expressed in weight of the total weight of the tablet. And also a process comprising: sieving and mixing of components except for the lubricant agent; mixing of all components; and direct compression of the final mixture. The tablets of the invention give lower disintegration times as well as good perception on the tongue after disintegration, and overcome the problem of insufficient mechanical resistance for packaging and transport operations.

The invention provides orally disintegrating tablets that readily disintegrates in the mouth, releasing enteric coated drug sub-tablets.